PL3468949T3 - Farmaceutyczne krystaliczne kokryształy bromku glikopironium i laktozy - Google Patents

Farmaceutyczne krystaliczne kokryształy bromku glikopironium i laktozy

Info

Publication number
PL3468949T3
PL3468949T3 PL17732540T PL17732540T PL3468949T3 PL 3468949 T3 PL3468949 T3 PL 3468949T3 PL 17732540 T PL17732540 T PL 17732540T PL 17732540 T PL17732540 T PL 17732540T PL 3468949 T3 PL3468949 T3 PL 3468949T3
Authority
PL
Poland
Prior art keywords
lactose
crystals
glycopyrronium bromide
crystalline pharmaceutical
crystalline
Prior art date
Application number
PL17732540T
Other languages
English (en)
Inventor
Zita Mendes
Tiago FONSECA
Original Assignee
Hovione Scientia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Scientia Limited filed Critical Hovione Scientia Limited
Publication of PL3468949T3 publication Critical patent/PL3468949T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
PL17732540T 2016-06-08 2017-06-08 Farmaceutyczne krystaliczne kokryształy bromku glikopironium i laktozy PL3468949T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PT10944516A PT109445B (pt) 2016-06-08 2016-06-08 Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
PT16109445 2016-06-08
PCT/GB2017/051664 WO2017212273A1 (en) 2016-06-08 2017-06-08 Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose
EP17732540.4A EP3468949B1 (en) 2016-06-08 2017-06-08 Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose

Publications (1)

Publication Number Publication Date
PL3468949T3 true PL3468949T3 (pl) 2022-01-10

Family

ID=59153215

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17732540T PL3468949T3 (pl) 2016-06-08 2017-06-08 Farmaceutyczne krystaliczne kokryształy bromku glikopironium i laktozy

Country Status (13)

Country Link
US (1) US10662152B2 (pl)
EP (1) EP3468949B1 (pl)
JP (1) JP7049270B2 (pl)
CN (1) CN109476593A (pl)
AU (1) AU2017278484B2 (pl)
CA (1) CA3026777A1 (pl)
DK (1) DK3468949T3 (pl)
ES (1) ES2898774T3 (pl)
HU (1) HUE057467T2 (pl)
IL (1) IL263534A (pl)
PL (1) PL3468949T3 (pl)
PT (1) PT109445B (pl)
WO (1) WO2017212273A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT109445B (pt) 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840002646A (ko) 1981-12-09 1984-07-16 고니시 진우에몬 구급용 반창고
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5403588A (en) 1993-11-23 1995-04-04 Santa Ana, Jr.; Cesareo T. Disposable body deodorant pad and deodorant preparation therefor
US5919760A (en) 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6214792B1 (en) 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
US6433003B1 (en) * 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
GB0504463D0 (en) * 2005-03-03 2005-04-13 Arakis Ltd Method of crystallisation and purification
ES2969237T3 (es) 2007-10-18 2024-05-17 Rose U Llc Formulaciones tópicas de glicopirrolato y una toallita que contiene las mismas
MX2011000410A (es) 2008-07-18 2011-03-24 Prosonix Ltd Proceso para mejorar la cristalinidad de particulas de fluticasona.
CN101756942B (zh) * 2008-12-25 2012-05-23 天津金耀集团有限公司 一种经口腔用肺吸入粉雾剂
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
CN102451173B (zh) * 2010-10-22 2015-02-18 山东新时代药业有限公司 噻托溴铵胶囊型吸入粉雾剂
EP2675439A2 (en) * 2011-02-17 2013-12-25 Cipla Limited Combination of glycopyrrolate and a beta2 -agonist
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
AU2013100007B4 (en) 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PT107166B (pt) 2013-09-16 2018-12-28 Hovione Farm S A Síntese e engenharia de partículas de cocristais
EP2913332A1 (en) * 2014-02-27 2015-09-02 Euticals S.P.A. Crystalline form of tiotropium bromide with lactose
FR3023177B1 (fr) 2014-07-04 2016-08-12 Centre Nat De La Rech Scient (C N R S) Procede de preparation de co-cristaux par evaporation flash
WO2016071862A1 (en) * 2014-11-05 2016-05-12 Glenmark Pharmaceuticals Limited Inhalable pharmaceutical composition comprising glycopyrronium
PT109445B (pt) 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose

Also Published As

Publication number Publication date
PT109445A (pt) 2017-12-11
WO2017212273A1 (en) 2017-12-14
CN109476593A (zh) 2019-03-15
JP7049270B2 (ja) 2022-04-06
AU2017278484A1 (en) 2018-12-20
EP3468949B1 (en) 2021-08-25
US10662152B2 (en) 2020-05-26
HUE057467T2 (hu) 2022-05-28
AU2017278484B2 (en) 2020-10-22
US20190256463A1 (en) 2019-08-22
ES2898774T3 (es) 2022-03-08
JP2019521974A (ja) 2019-08-08
EP3468949A1 (en) 2019-04-17
IL263534A (en) 2019-01-31
DK3468949T3 (da) 2021-11-15
PT109445B (pt) 2018-11-06
CA3026777A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
ME03740B (me) Jedinjenja indol karboksamida korisna kao inhibitori kinaze
IL254655B (en) Ibrutinib co-crystal
GB201501583D0 (en) Uses of co-crystals
IL246807A0 (en) Agrochemical compounds for improving crop production
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
EP3337485A4 (en) CRYSTALLINE FORMS OF IBRUTINIB
HK1244274A1 (zh) C21h22ci2n4o2的晶型
IL266589A (en) A process for the preparation of omclidinium bromide
EP3193609A4 (en) Substituted pyrrolidine carboxamide compounds
PT3113773T (pt) Formas cristalinas do grapiprant
IL253479A0 (en) Crystalline forms of efinconazole
GB201417252D0 (en) Tripod head
ZA201704795B (en) Novel crystal forms of the monosodium salt of foramsulfuron
IL263534A (en) Co-crystals of glycopyrronium bromide and lactose suitable for use in pharmaceutical preparations
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
IL252944B (en) Granticin B polymorph
PT3110814T (pt) Forma cristalina de brometo de tiotrópio com lactose
GB201402377D0 (en) Stable polymorph form B of tapentadol hydrochloride
HK1244006A1 (zh) Parp抑制劑的結晶形式
PT3377478T (pt) Co-cristais de bilastina